Final OS Results From MARIPOSA Trial in EGFR-Mutant NSCLC

Nicolas Girard, MD, PhD, a thoracic oncologist at the Institut Curie in Paris, France, discusses the final overall survival results from the MARIPOSA trial (NCT04487080) of amivantamab-vmjw (Rybrevant) plus lazertinib (Leclaza) vs osimertinib (Tagrisso) as a first-line treatment for patients with EGFR-mutant advanced non–small cell lung cancer. These findings were presented at the 2025 European Lung Cancer Congress (ELCC).

Transcription:

0:10 | At ELCC 2025, we saw the final overall analysis results from the MARIPOSA trial. MARIPOSA is a first-line EGFR-mutant, non–small cell lung cancer trial that assesses the combination of amivantamab plus lazertinib vs the historical standard-of-care, which is osimertinib. This is a very large trial that holds more than 1000 patients. The primary end point was progression-free survival, and we saw the results previously with amivantamab plus lazertinib, significantly prolonging progression-free survival vs osimertinib, moving from 17 months with osimertinib to nearly 24 months with amivantamab plus lazertinib. This is a ratio of 0.70, and this led to the approval of MARIPOSA in several countries in Europe.

1:10 | Now at ELCC, we have just seen the overall survival results. Overall survival is a very important end point for us because it shows how PFS benefit may translate into prolonged survival for the patients. And actually, at the final overall survival analysis of MARIPOSA, we have a strong benefit with amivantamab plus lazertinib vs osimertinib, more than a 12-month difference between the standard control arm of osimertinib and amivantamab plus lazertinib. This is a hazard ratio of 0.75, and the median overall survival with osimertinib was 17 months.

1:59 | In line with what was reported historically with amivantamab plus lazertinib, the median is not reached already, but the lower boundary of the confidence interval is about 43 months, so we expect this 12-month difference. So, it shows that the benefits that we have in the first-line setting translate in the long-term to an overall survival benefit, which is at the end, leading amivantamab plus lazertinib to be the new standard of care for the first-line treatment of those patients.